Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.47 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.47 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.47 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.47 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.47 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.46 |
| ▸ | OPRD1 known ✓ | P41143 | 3/20 | 0.44 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.43 |
| ▸ | KCNA3 known ✓ | P22001 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48800 | 0.98 | OPRM1 (0.48) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| SCHEMBL19281773 | 0.96 | OPRM1 (0.47) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL5198335 | 0.91 | OPRM1 (0.41) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| Aminodiphenylmethane SCHEMBL9192661 | 0.89 | ALDH1A1 (0.44) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| SCHEMBL24238295 | 0.87 | OPRM1 (0.41) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| SCHEMBL20133104 | 0.87 | OPRM1 (0.54) | OPRM1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL24238319 | 0.87 | OPRM1 (0.54) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| SCHEMBL24238338 | 0.87 | OPRM1 (0.54) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| SCHEMBL5745379 | 0.86 | CYP2D6 (0.47) | OPRM1KMT2AMEN1CHRM2CHRM4 | |
| SCHEMBL2267354 | 0.82 | L3MBTL3 (0.53) | OPRM1KMT2AMEN1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104356040-A | Preparation method of 1-benzhydryl-3-hydroxylazetidine hydrochloride | ASTATECH CHENGDU BIOPHARM CO LTD | 2015-02-18 | — | — | CN | claimed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240368171-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| EP-4157831-B1 | PROCESSES OF PREPARING A JAK1 INHIBITOR | INCYTE CORP (US) | 2024-10-30 | — | — | EP | disclosed |
| US-12071439-B2 | Process and intermediates for preparing a JAK inhibitor | INCYTE CORPORATION (US) | 2024-08-27 | — | — | US | disclosed |
| CN-118317946-A | Processes and intermediates for the preparation of baratinib | 因赛特公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4370504-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-112105608-B | Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one | 因赛特公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11685731-B2 | Processes of preparing a JAK1 inhibitor | INCYTE CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4157831-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR | Incyte Corporation (US) | 2023-04-05 | — | — | EP | disclosed |
| US-5183902-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-02-02 | — | — | US | disclosed |
| US-5151418-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-09-29 | — | — | US | disclosed |
| US-5130309-A | Cardiovascular disorders | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-07-14 | — | — | US | disclosed |
| US-5068231-A | Ureas and thioureas for relaxing muscles | A. H. ROBINS COMPANY INCORPORATED (US) | 1991-11-26 | — | — | US | disclosed |
| US-4956359-A | CARBOXAMIDES OR THIOCARBOXAMIDES OF ARYL OXY OR THIO AZETIDINES | A. H. ROBINS COMPANY, INC. (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0194112-B1 | 3-ARYL-OXYAZETIDINECARBOXAMIDES HAVING ANTI-MUSCLE TENSION, ANTI-MUSCLE SPASTICITY, ANTICONVULSANT AND ANTIEPILECTIC ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0131435-B1 | PROCESS FOR PREPARING 3-PHENOXY-1-AZETIDINES AND CARBOXAMIDE DERIVATIVES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-10-07 | — | — | EP | disclosed |
| EP-0194112-A1 | 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-09-10 | — | — | EP | disclosed |
| US-4594189-A | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A. H. ROBINS COMPANY, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0131435-A1 | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368171-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | JAK2, JAK1, JAK3 | OPRM1 4363/4885CHRM2 4874/4885CHRM4 4864/4885 |
| US-12071439-B2 | Process and intermediates for preparing a JAK inhibitor | JAK2, JAK1, JAK3 | OPRM1 4363/4885CHRM2 4874/4885CHRM4 4864/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | OPRM1 2352/4885CHRM2 4559/4885CHRM4 4807/4885 |
| US-11685731-B2 | Processes of preparing a JAK1 inhibitor | JAK1, JAK2, JAK3 | OPRM1 2931/4885CHRM2 4870/4885CHRM4 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.